Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

NCT07021989 is registered in ClinicalTrials.gov with Michael Spinner, MD as lead sponsor.

NCT NCT07021989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07021989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium
Lead sponsor
Michael Spinner, MD
Phase
Phase 2
Overall status
Recruiting
Start date
August 18, 2026
Completion date
March 31, 2034
Enrollment
38 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

classic hodgkin lymphoma, hodgkin lymphoma, adult, refractory hodgkin lymphoma